Document is current
Any future updates will be listed below
-
Authors
Ortmann, O.
Schüler-Toprak, S.
Kast, K.
,
Fehm, T.
Hahne, A.
Huber, D.
Kühnle, E.
Mohr, K.
Rhiem, K.
Seitz, S.
Speiser, D.
-
Funding
Funding for this research was provided by:
Universitätsklinikum Regensburg
- License Information
-
More Information
Article History
Received: 31 July 2024
Accepted: 30 August 2024
First Online: 11 September 2024
Declarations
:
: Financial interests: O.O.: O.O. has received speaker honorarium from AstraZeneca; Astellas Pharma; Novartis Pharma and ownes stocks of Novartis, Bayer, Fresenius Medical Care, Curevac, Morphosys S.S.-T.: SST received speaker honorarium from Pfizer, Roche and author honorarium from thieme and further training was supported by GSK and Celgene K.K.: Honorary, advisory board, Pfizer Pharma Non-financial interests: O.O.: Memberships: Member of the Board of the German Cancer Society, Board of Trustees of German Cancer Aid, Member of the Board of ADT; Memberships of professional associations: German Society for Gynecology and Obstetrics—Gynecological Oncology Working Group, Kommission OVAR; German Society for Senology; German Society for Endocrinology; Working Group for Gynecologic Oncology; German Cancer Society; Bavarian Cancer Society; Bavarian Society for Obstetrics and Gynecology; Coordinator of the S3 guideline “Peri- and Postmenopause—Diagnostics and Interventions”; Mandate holder for the DKG Certification Commission for Gynecological Cancer Centers S.S.-T.: SST is Member of the Working Group for Cervical Pathology and Colposcopy (AG-CPC); Member of the German Society for Gynecology and Obstetrics (DGGG); Member of the Working Group for Gynecologic Oncology (AGO) and the Kommission OVAR and Member of the German Cancer Society (DKG) K.K.: none.
: This is a systematic review. No ethical approval is required.
